Backgroud: Currently, partial hepatectomy is the mainly treatment for early stage of primary hepatocellular carcinoma(HCC). Meanwhile, the most important factor affecting the long-term survival for patients with HCC is tumor recurrence after surgery. Variety of hemostatic agents were widely used in clinical to reduce the amount of bleeding during or after hepatectomy. However, there is lack of research whether tumor recurrence after hepatectomy is related to perioperative hemostatic agents used. Methods: 504 cases of patients underwent hepatectomy with diameter of HCC less than 5cm, stage of tumor on T1-2N0M0, liver function on Child-Pugh score A , B grade as well as pathological negative margins during 2005-2007 in our hospital were collected in this study. Cox model with stepwise regression analysis was used to find out the factors related to survival of patients and recurrence after surgery, and Kaplan-Meier analysis was used to clear whether the use of intravenous hemostatic agent is related to overall survival time (OS ) as well as recurrence - free survival time (RFS ). Results: The median follow-up time for all patients is 64 months ( 7-72 months). For all 504 patients, the perioperative intravenous hemostatic agents used was 326 cases and 178 cases did not receive any hemostatic agents during the perioperative period. Compared with patients recieved no hemostatic agents, 5-year OS rate is lower ( 61.04% vs 75.28%, P=0.002 ) as well as 5-year RFS rate is lower (49.08% vs 61.80%，P=0.001) on patients received perioperative intravenous hemostatic agents. Meanwhile, perioperative use of intravenous hemostatic agents is an independent risk factor on patients’ OS ( P = 0.002 relative risk 1.759,95 % CI :1.277 - 2 .521 ) and RFS ( P = 0.005 relative risk 1.523,95 % CI :1.136 -2 .043 ). Conclusion: Perioperative use of intravenous hemostatic agents reduce overall survival and recurrence-free survival time for patients after hepatectomy.